Related Experiment Video
Updated: Jan 7, 2026
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Engineered flagellin-based adjuvant boosts mucosal immunity in recombinant RSV vaccine
Guoguo Ye1, Changbin Qu2, Zhi Liao3
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China; Guangzhou National Laboratory, Guangzhou 510005, China.
A novel adjuvant (FIC) enhances respiratory syncytial virus (RSV) vaccines by boosting mucosal immunity in mice. This approach shows promise for developing safer and more effective pediatric RSV vaccines, overcoming past safety concerns.
Area of Science:
- Vaccinology
- Immunology
- Microbiology
Background:
- Respiratory syncytial virus (RSV) is a major threat to young children.
- Past RSV vaccine development faced safety issues like vaccine-associated enhanced respiratory disease (VAERD).
Purpose of the Study:
- To develop a safe and effective RSV vaccine adjuvant.
- To enhance mucosal immunity against RSV infections.
Main Methods:
- Engineered a deimmunized flagellin-derived adjuvant (FIC).
- Tested FIC-adjuvanted RSV prefusion F (preF) vaccines in mouse models.
- Evaluated immune responses, including Th1 bias and cytokine production (IFN-γ, IL-2, TNF-α).
- Assessed protection against RSV challenges using sequential intranasal immunization.
Main Results:
- FIC adjuvant induced a Th1-biased immune response and robust pre-F-specific immunity.
- Minimized flagellin-associated immunogenicity.
- Sequential immunization with FIC significantly improved protection against RSV in upper and lower respiratory tracts.
- Intranasal immunization enhanced antigen-specific cytokine production.
Conclusions:
- Structure-guided adjuvant optimization with mucosal prime-boost strategies can overcome historical RSV vaccine barriers.
- FIC adjuvant offers a promising pathway for developing safe and effective pediatric RSV vaccines.
More Related Videos
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
16:56Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
